Clinical trial
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic…
NCT00430846 · Seagen Inc., Industry · Completed
Key facts
| NCT number | NCT00430846 |
|---|---|
| Title | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies |
| Official title | A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies. |
| Lead sponsor | Seagen Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin, Disease, Hodgkin, Large-Cell, Anaplastic |
| Intervention type | Drug |
| Interventions | SGN-35 |
| Enrollment | 45 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Feb 2, 2007 |
| Last update posted | Dec 18, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: